Rapid cellular enrichment of eicosapentaenoate after a single intravenous injection of a novel medium-chain triacylglycerol:fish-oil emulsion in humans

BACKGROUND: Dietary deficiency in n-3 (omega-3) polyunsaturated fatty acids (PUFAs) prevails in Western populations and potentially results in adverse health outcomes. To circumvent the slow n-3 PUFA incorporation in phospholipids of key cells after oral supplementation, a new preparation for intrav...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of clinical nutrition Vol. 91; no. 4; pp. 875 - 882
Main Authors Carpentier, Yvon A, Hacquebard, Mirjam, Portois, Laurence, Dupont, Isabelle E, Deckelbaum, Richard J, Malaisse, Willy J
Format Journal Article
LanguageEnglish
Published Bethesda, MD American Society for Clinical Nutrition 01.04.2010
American Society for Nutrition
American Society for Clinical Nutrition, Inc
Subjects
Online AccessGet full text
ISSN0002-9165
1938-3207
1938-3207
DOI10.3945/ajcn.2009.27951

Cover

Loading…
More Information
Summary:BACKGROUND: Dietary deficiency in n-3 (omega-3) polyunsaturated fatty acids (PUFAs) prevails in Western populations and potentially results in adverse health outcomes. To circumvent the slow n-3 PUFA incorporation in phospholipids of key cells after oral supplementation, a new preparation for intravenous bolus injection was developed with 20 g triacylglycerols/100 mL of a mixture of 80% medium-chain triacylglycerols (MCTs) and 20% fish oil (FO) (wt:wt), and 0.4 g α-tocopherol/100 mL of the same mixture. OBJECTIVE: Our objective was to document the enrichment of n-3 PUFAs in leukocyte and platelet phospholipids after a bolus intravenous injection of MCT:FO in men. DESIGN: Twelve healthy male subjects received injections over a 5-min period of 50 mL of either MCT:FO or a control MCT:long-chain triacylglycerol (MCT:LCT) emulsion containing 20 g triacylglycerols/100 mL with equal amounts (wt:wt) of MCT and soybean triacylglycerols (LCT) and containing 0.02 g α-tocopherol/100 mL; after an 8-wk interval, the subjects received injections of the other preparation. RESULTS: Clinical and biological variables that assessed tolerance and safety remained unchanged. Plasma elimination was faster for MCT:FO than for MCT:LCT (half-life: 24.5 ± 3.5 min compared with 32.9 ± 3.0 min; P < 0.025). This was associated with a greater increase in the plasma nonesterified fatty acid concentration. The content of n-3 PUFAs, specifically eicosapentaenoic acid (20:5n-3), increased in leukocyte and platelet phospholipids within 60 min and ≥24 h after MCT:FO injection. CONCLUSION: Bolus intravenous injection of a novel MCT:FO emulsion allows rapid enrichment of cells with n-3 PUFAs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
Supported by grant RBC-BR 246/2410 from the Région de Bruxelles-Capitale (Brussels, Belgium) to Target Hit sa (Brussels, Belgium); YAC, LP, IED, and WJM were also affiliated with Target Hit sa. Also supported by grant HL-40404 from the National Institutes of Health to RJD and by B Braun Melsungen AG (Melsungen, Germany). Emulsions were provided by B Braun Melsungen AG.
ISSN:0002-9165
1938-3207
1938-3207
DOI:10.3945/ajcn.2009.27951